leadf
logo-loader
viewKintara Therapeutics

DelMar Pharmaceuticals races up on Nasdaq on brain cancer clinical trial news

DelMar's VAL-083 STAR-3 GBM trial is a clinical study in patients with brain cancer

shutterstock_118491940.jpg
Glioblastoma (GBM) is the most common and aggressive primary brain cancer

Shares in Cancer therapy focused firm DelMar Pharmaceuticals (NASDAQ: DMPI) added over 19% to $2.21 in New York as it received the green light to conduct a pivotal Phase 3 study.

DelMar's VAL-083 STAR-3 GBM trial is a randomized, controlled clinical trial in patients with glioblastoma multiforme (GBM) whose disease has progressed following prior treatment with temozolomide and bevacizumab.

Enrollment to open..

Chairman and chief executive Jeffrey Bacha said: "We are pleased to remain on track to open enrollment in this trial at leading centers in the United States. 

"Based on our research, we believe that VAL-083 offers significant potential as a new therapy for GBM patients who currently have no viable treatment options."

Up to 180 patients..

Up to 180 eligible patients will be randomized at 25 centers in the United States to receive either the investigational drug (VAL-083) or "investigator's choice salvage therapy" as a contemporaneous control.

Glioblastoma (GBM) is the most common and aggressive primary brain cancer.

Current standard of care includes surgery, radiation and treatment with temozolomide (TMZ), however nearly all tumors recur and the prognosis for the recurrent form of the disease is dismal.

Quick facts: Kintara Therapeutics

Price: 1.71 USD

NASDAQ:KTRA
Market: NASDAQ
Market Cap: $52.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kintara Therapeutics named herein, including the promotion by the Company of Kintara Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read